Literature DB >> 23287562

Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88).

Hidetoshi Nitta1, Yoshihiro Wada, Yoshiaki Kawano, Yoji Murakami, Atsushi Irie, Keisuke Taniguchi, Ken Kikuchi, Gen Yamada, Kentaro Suzuki, Jiro Honda, Masayo Wilson-Morifuji, Norie Araki, Masatoshi Eto, Hideo Baba, Takahisa Imamura.   

Abstract

PURPOSE: The anaphylatoxin C5a is a chemoattractant that induces leukocyte migration via C5a receptor (C5aR). There is emerging evidence that C5a is generated in the cancer microenvironment. We therefore sought C5aR expression and a direct influence of the C5a-C5aR axis on cancer cells. EXPERIMENTAL
DESIGN: C5aR expression was investigated in human cancer tissues and cell lines. Effects of C5a stimulation on cancer cells were studied by cytoskeletal rearrangement, time-lapse analysis, Matrigel chamber assay, and invasion in nude mouse in a comparison of C5aR-expressing cancer cells with control cells.
RESULTS: C5aR was aberrantly expressed in various human cancers. Several cancer cell lines also expressed C5aR. C5a triggered cytoskeletal rearrangement and enhanced cell motility three-fold and invasiveness 13-fold of C5aR-expressing cancer cells. Such enhancement by C5a was not observed in control cells. Cancer cell invasion was still enhanced in the absence of C5a concentration gradient and even after the removal of C5a stimulation, suggesting that random cell locomotion plays an important role in C5a-triggered cancer cell invasion. C5a increased the release of matrix metalloproteinases (MMP) from cancer cells by two- to 11-fold, and inhibition of MMP activity abolished the C5a-enhancing effect on cancer cell invasion. Compared with control cells, C5aR-expressing cells spread 1.8-fold more broadly at implanted nude mouse skin sites only when stimulated with C5a.
CONCLUSIONS: These results illustrate a novel activity of the C5a-C5aR axis that promotes cancer cell invasion through motility activation and MMP release. Targeting this signaling pathway may provide a useful therapeutic option for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23287562     DOI: 10.1158/1078-0432.CCR-12-1204

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  33 in total

1.  Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus.

Authors:  Alok K Shah; Gunter Hartel; Ian Brown; Clay Winterford; Renhua Na; Kim-Anh Lê Cao; Bradley A Spicer; Michelle A Dunstone; Wayne A Phillips; Reginald V Lord; Andrew P Barbour; David I Watson; Virendra Joshi; David C Whiteman; Michelle M Hill
Journal:  Mol Cell Proteomics       Date:  2018-08-10       Impact factor: 5.911

2.  C5a receptor expression is associated with poor prognosis in urothelial cell carcinoma patients treated with radical cystectomy or nephroureterectomy.

Authors:  Yoshihiro Wada; Yoshihiro Maeda; Tatsuko Kubo; Ken Kikuchi; Masatoshi Eto; Takahisa Imamura
Journal:  Oncol Lett       Date:  2016-09-15       Impact factor: 2.967

Review 3.  Complement in cancer: untangling an intricate relationship.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; Alberto Mantovani; John D Lambris
Journal:  Nat Rev Immunol       Date:  2017-09-18       Impact factor: 53.106

Review 4.  The role of the complement system in cancer.

Authors:  Vahid Afshar-Kharghan
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

5.  Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects.

Authors:  Daniel Ajona; Carolina Zandueta; Leticia Corrales; Haritz Moreno; María J Pajares; Sergio Ortiz-Espinosa; Elena Martínez-Terroba; Naiara Perurena; Fernando J de Miguel; Eloisa Jantus-Lewintre; Carlos Camps; Silvestre Vicent; Jackeline Agorreta; Luis M Montuenga; Ruben Pio; Fernando Lecanda
Journal:  Am J Respir Crit Care Med       Date:  2018-05-01       Impact factor: 21.405

Review 6.  Immunological effects and therapeutic role of C5a in cancer.

Authors:  Victoria R Darling; Ralph J Hauke; Stefano Tarantolo; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2014-11-12       Impact factor: 4.473

7.  Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2.

Authors:  Julien Cherfils-Vicini; Charlene Iltis; Ludovic Cervera; Sabrina Pisano; Olivier Croce; Nori Sadouni; Balázs Győrffy; Romy Collet; Valérie M Renault; Martin Rey-Millet; Carlo Leonetti; Pasquale Zizza; Fabrice Allain; Francois Ghiringhelli; Nicolas Soubeiran; Marina Shkreli; Eric Vivier; Annamaria Biroccio; Eric Gilson
Journal:  EMBO J       Date:  2019-04-18       Impact factor: 11.598

8.  Dissecting characteristics and dynamics of differentially expressed proteins during multistage carcinogenesis of human colorectal cancer.

Authors:  Fang Peng; Ying Huang; Mao-Yu Li; Guo-Qing Li; Hui-Chao Huang; Rui Guan; Zhu-Chu Chen; Song-Ping Liang; Yong-Heng Chen
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

9.  Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes.

Authors:  Hidetoshi Nitta; Takayuki Shimose; Yasunori Emi; Takahisa Imamura; Koji Ohnishi; Tetsuya Kusumoto; Manabu Yamamoto; Kengo Fukuzawa; Ikuo Takahashi; Hidefumi Higashi; Akihito Tsuji; Yoshito Akagi; Eiji Oki; Yoshihiko Maehara; Hideo Baba
Journal:  Med Oncol       Date:  2016-09-29       Impact factor: 3.064

10.  Plasma protein biomarkers of hepatocellular carcinoma in HCV-infected alcoholic patients with cirrhosis.

Authors:  Gustavo Ferrín; Manuel Rodríguez-Perálvarez; Patricia Aguilar-Melero; Isidora Ranchal; Camilo Llamoza; Clara I Linares; Sandra González-Rubio; Jordi Muntané; Javier Briceño; Pedro López-Cillero; José Luis Montero-Álvarez; Manuel de la Mata
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.